Publicaciones en colaboración con investigadores/as de Instituto de Salud Carlos III (12)

2020

  1. Treatment patterns for metastatic colorectal cancer in Spain

    Clinical and Translational Oncology, Vol. 22, Núm. 9, pp. 1455-1462

2018

  1. Novel genetic mutations detected by multigene panel are associated with hereditary colorectal cancer predisposition

    PLoS ONE, Vol. 13, Núm. 9

2016

  1. Risk-adapted adjuvant chemotherapy after concomitant fluoropyrimidine-radiotherapy neoadjuvant treatment for patients with resectable CT3-4 or N+ rectal cancer: Five-year disease-free survival results of a single-center series

    Clinical Colorectal Cancer, Vol. 15, Núm. 2, pp. 128-134

2015

  1. First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: A phase II study of the Spanish cooperative group for the treatment of digestive tumours

    European Journal of Cancer, Vol. 51, Núm. 11, pp. 1371-1380

  2. Phase II trial of miniDOX (reduced dose docetaxel-oxaliplatin-capecitabine) in "suboptimal" patients with advanced gastric cancer (AGC). TTD 08-02

    Cancer Chemotherapy and Pharmacology, Vol. 75, Núm. 2, pp. 319-324

2014

  1. TTD consensus document on the diagnosis and management of exocrine pancreatic cancer

    Clinical and Translational Oncology, Vol. 16, Núm. 10, pp. 865-878

2012

  1. Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: A spanish cooperative group for the treatment of digestive tumors study

    Oncologist, Vol. 17, Núm. 7, pp. 947-955

  2. First-Line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study

    Onkologie, Vol. 6, Núm. 2, pp. 96-103

  3. First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: Clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD group study

    Oncologist, Vol. 17, Núm. 3, pp. 339-345

2011

  1. First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD)

    Critical Reviews in Oncology/Hematology, Vol. 77, Núm. 1, pp. 78-84

  2. Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer

    Breast Cancer Research and Treatment, Vol. 128, Núm. 1, pp. 127-136

2010

  1. Breast cancer: Complete response with the combination of sunitinib and trastuzumab in a patient with grade III ductal carcinoma

    Anti-Cancer Drugs, Vol. 21, Núm. SUPPL.1